Skip to main content
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies
- Frange, Pierre;
- Assoumou, Lambert;
- Descamps, Diane;
- Chéret, Antoine;
- Goujard, Cécile;
- Tran, Laurent;
- Gousset, Marine;
- Avettand-Fenoël, Veronique;
- Bocket, Laurence;
- Fafi-Kremer, Samira;
- Guinard, Jerome;
- Morand-Joubert, Laurence;
- Nicot, Florence;
- Plantier, Jean-Christophe;
- Rogez, Sylvie;
- Wirden, Marc;
- Rouzioux, Christine;
- Meyer, Laurence;
- Chaix, Marie-Laure;
- Abel, S;
- Abraham, B;
- Allegre, T;
- Antoniotti, A;
- Armero, R;
- Audhuy, B;
- Aumaitre, H;
- Beaucaire, G;
- Beck-Wirth, G;
- Berger, JL;
- Bernard, L;
- Beuscart, C;
- Bodard, L;
- Bouchaud, O;
- Boué, F;
- Cabane, J-P;
- Cabie, A;
- Champagne, H;
- Cheneau, C;
- Chennebault, J-M;
- Cheret, A;
- Christian, B;
- Compagnucci, A;
- Daneluzzi, V;
- Debab, Y;
- Dellamonica, P;
- Delfraissy, J-F;
- Devidas, A;
- Diab, G;
- Doll, J;
- Drobacheff-Thebaut, MC;
- Durel, A;
- Duvivier, C;
- Esnault, J-L;
- Faba, L;
- Froguel, E;
- Garipuy, D;
- Garrait, V;
- Geffray, L;
- Genet, C;
- Genet, P;
- Gerard, L;
- Ghosn, J;
- Girard, J-J;
- Girard, P-M;
- Godin-Collet, C;
- Hochedez, P;
- Hoen, B;
- Houlbert, D;
- Jacomet, C;
- Jeantils, V;
- Jidar, K;
- Katlama, C;
- Klement, E;
- Lafeuillade, A;
- Lascoux, C;
- Launay, V;
- Lepretre, A;
- Levy, Y;
- Makhloufi, D;
- Malbec, D;
- Martha, B;
- May, T;
- Merrien, D;
- Miailhes, P;
- Miodovski, C;
- Molina, J-M;
- Morlat, P;
- Mortier, E;
- Neau, D;
- Obadia, M;
- Patey, O;
- Pellegrin, J-L;
- Perronne, V;
- Philibert, P;
- Pialoux, G;
- Pichancourt, G;
- Piroth, L;
- Poinsignon, Y;
- Poizot-Martin, I;
- Prazuck, T;
- Prendki, V;
- du Clary, F Preveteau;
- Quinsat, D;
- Raffi, F;
- Regnier, A;
- Reynes, J;
- Rosenthal, E;
- Rouveix, E;
- Salmon, D;
- Salanville, F;
- Schmitt, J-L;
- Simon-Coutellier, A;
- Sotto, A;
- Souala, F;
- Stein, A;
- Timsit, F;
- de Truchis, P;
- Uludag, A;
- Vaillant, O;
- Verdon, R;
- Verlesch-Langlin, A;
- Viard, J-P;
- Vittecoq, D;
- Weiss, L;
- Yéni, P;
- Zucman, D;
- Allavena, C;
- Allegre, T;
- Amri, I;
- Autran, B;
- Bacchus, C;
- Blanc, C;
- Bonne, S;
- Bonnet, B;
- Bouchez, S;
- Charlier, C;
- Consigny, P-H;
- Duvivier, C;
- Fourn, E;
- Guiroy, F;
- Huleux, T;
- Katlama, C;
- Lascoux-Combe, C;
- Leplatois, A;
- Lyavanc, T;
- Molina, J-M;
- Naqvi, A;
- Nembot, G;
- Quertainmont, Y;
- Raffi, F;
- Samri, A;
- Schneider, L;
- Seang, S;
- Seksik, BCP;
- Shoai-Tehrani, M;
- Slama, L;
- Valentin, M-A;
- Yazdanpanah, Y;
- Alloui, C;
- Amiel, C;
- André, P;
- André-Garnier, E;
- Anies, G;
- Barin, F;
- Bellecave, P;
- Bettinger, D;
- Bouvier-Alias, M;
- Brun-Vézinet, F;
- Calmy, A;
- Calvez, V;
- Caveng, W;
- Chaillon, A;
- Chapalay, S;
- Charpentier, C;
- Costagliola, D;
- Cottalorda, J;
- Delamare, C;
- Delaugerre, C;
- Dina, J;
- Santos, G Dos;
- Férré, V;
- Flandre, P;
- Fleury, H;
- Fourati, S;
- Gaille, C;
- Giraudeau, G;
- Guigon, A;
- Haim-Boukobza, S;
- Lagier, E;
- Le Guillou-Guillemette, H;
- Henquell, C;
- Izopet, J;
- Lambert-Niclot, S;
- Leroux, M;
- Maillard, A;
- Malet, I;
- Marcelin, A-G;
- Marque-Juillet, S;
- Masquelier, B;
- Mirand, A;
- Morand, P;
- Montes, B;
- Mouna, L;
- Noel, C;
- Pallier, C;
- Peytavin, G;
- Pinson-Recordon, P;
- Poveda, JD;
- Raymond, S;
- Reigadas, S;
- Roques, A-M;
- de Rougemont, A;
- Roussel, C;
- Schmitt, M-P;
- Schneider, V;
- Schvoerer, E;
- Signori-Schmuck, A;
- Soulié, C;
- Tamalet, C;
- Tardy, JC;
- Trabaud, M-A;
- Vabret, A;
- Vallet, S;
- Yerly, S
- et al.
Published Web Location
https://academic.oup.com/jac/article/70/7/2084/774670No data is associated with this publication.
Abstract
Background
Our study describes the prevalence of transmitted drug resistance (TDR) among 1318 French patients diagnosed at the time of primary HIV-1 infection (PHI) in 2007-12.Methods
HIV-1 resistance-associated mutations (RAMs) were characterized using both the 2009 WHO list of mutations and the French ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended ART combination.Results
Patients were mainly MSM (72.6%). Non-B variants were identified in 33.7% of patients. The proportion of TDR was estimated as 11.7% (95% CI 10.0-13.5). The prevalences of PI-, NRTI-, first-generation NNRTI and etravirine/rilpivirine-associated RAMs were 2.5%, 5.2%, 3.9% and 3.2%, respectively. Single, dual and triple class resistance was found in 9.6%, 1.0% and 1.1% of cases, respectively. Additionally, 5/331 strains isolated in 2010-12 had integrase inhibitor (II)-related RAMs (isolated E157Q mutation in all cases). TDR was more common among MSM than in other groups (12.9% versus 8.6%, P = 0.034), and in case of B versus non-B subtype infections (13.6% versus 7.9%, P = 0.002). The proportions of fully active combinations were ≥99.2%, ≥97.3% and ≥95.3% in cases of PI-, II- and NNRTI-based regimens, respectively. In 2010-12, the proportion of fully active efavirenz-based ART was lower in cases of subtype B versus non-B infection (P = 0.021).Conclusions
Compared with our previous studies, the proportion of NRTI- and first-generation NNRTI-related TDR has continued to decline in French seroconverters. However, subtype B-infected MSM could drive the spread of resistant HIV strains. Finally, we suggest preferring PI- or II- to NNRTI-based combinations to treat PHI patients.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.